Anxa2 siRNA could inhibit prostate cancer growth without detectable adverse effects [117].These strategies might be the focus for further investigations on pharmaceutical intervention in renal cell cancer. This evidence concerns the gene ANXA2 and renal cell adenocarcinoma.